Member Info for Fadec92

Krusty/Potnak are you on Twitter?

Krustymegma, count me on that list, in any case people touting targets is a sure way of loosing money, you set your own targets based on your findings, whether it be charts you use or what the market is actually doing with what sort of news is around, I can’t see a buyout on an untested molecule in a human, I think there is too much risk for a bigger company, just because SRA737 was dosnt mean this will, I did think this initially but thing there are different factors involved!

I see that Innocare have another TYK2 that could go into trials this year, ICP-488, these guys seam too be keeping on track but offcourse China might now have the difficulty that Sareum has because of covid19!

“ICP-488 – a small molecule binder of the pseudokinase domain (Janus Homology 2 or JH2) of TYK2. We intend to develop ICP-488 for the treatment of inflammatory diseases such as psoriasis and IBD. We plan to file the IND application for ICP-488 in the second half of 2021.”

https://imgur.com/a/dF6Nqrx

https://portalvhds1fxb0jchzgjph.blob.core.windows.net/press-releases-attachments/1294025/HKEX-EPS_20210326_9674804_0.PDF

Should be able too complete the FEED, in that time!

In 2019 they said 2020
In 2020 they said 2021
Now in 2021 it’s 2022

Ok it’s Covid so can see the delay is real, but they did during the covid pandemic say they were unaffected by covid, now they are, is what it is but you can’t say this hasn’t dragged on and on!

SDC-1801 updated application in US office, no problem for SDC-1802 has a recent working Patent but would still like too hear the 16/343639 Patent which could be the T-ALL BCL-2 pathway, need more research on that, as they had too select one group or another whether it covers the solid tumors in the new one should be open for debate here, wish they did raise for 1802 as the poster presentation with AxisBio in combo with 5-FU looks promising but are not progressing due too funding!

I have no clue why you have asked me too substantiate the post if you knew already I just don’t see the point in any of this and just wasting people’s time here and mine, the duel/dual yep sums it up ok my spelling is not great who cares really, I’m not going too apologize for anything as I don’t think I need too really!

Sadoldgit you communicated in response to my post about my referring too the point I was making about patent protection that’s why I added 2 current molecules out of pre-clinical and into phase 1 that has patent protection as well as 1801, I named both molecules by identity number that’s clear and is in context!

I have now proved too you about TLL018 is a duel Tyk2/JAK1 inhibitor and the demand of source that you asked me too reveal, I have now cleared that up for you and was suggesting and hope you now agree after prove that the post was factual and just find it amazing that you hadn’t research this otherwise why ask!

You say I was keen on ICP-322 but posted the article from Robin from that current tweet so I’m not dropping in too suit my agenda!

The reason is too the condescending behavior is that i think your being a bit smarmy for no apparent reason as too put me and my posts down which I don’t like, bits like “dig a big hole for yourself” if you sling mud it’s going too come back, I haven’t been disrespectful too you so I don’t expect you too be!

Sadoldgit all this researching you should be doing yourself, it does make me wonder why I’m doing this and you should know this if your heavily invested it’s not new and I’ve posted it before anyhow, so there’s is no excuse!

JAK1 (IC50 = 4?nM) and TYK2 (IC50 = 5?nM)

https://ard.bmj.com/content/79/Suppl_1/252.1

https://imgur.com/a/gJzG5MB

With ICP-322 it only mentions the fold selectivity against JAK2 with JAK1 it dosnt, and presented it the same time the Article was tweeted by Robin Davidson!

In the pdf there’s this too but not much data, but if anyone finds any information on it please post!

https://imgur.com/a/dPGlM64

Sadoldgit I was Referencing TTL Pharma in first bit which it has completed as of March 2021, off the top of my head I think readout in June 2021!

“It’s not just 1801 that has patent protection (old protection) new one in application, as TLL Pharma (Should have completed Phase 1 trial) has US protection”

https://clinicaltrials.gov/ct2/show/NCT04243083

I don’t care if you think I have an agenda they are facts and can post them so all can know!

https://imgur.com/a/YuMLOlb

All the best too you Belhus, but unfortunately for you I will keep on presenting the facts however irate you get!

Citizen comments like nice try, and other people understand the science and timing of posts, I think you are reading too much into this, it’s simple and don’t want too get into long discussions he said this and that, I’m not interested really!

As a side note I’ve haven’t said much about attacks on my, but reading lots of horrible posts, people who are...you’re acting like schoolgirls on the playground, I’m assuming you are all grownups and only pointing out my views from what I read that’s it, play the ball not the man and sort it out please!

Two points I’m picking up from the posts!

It’s not just 1801 that has patent protection (old protection) new one in application, as TLL Pharma (Should have completed Phase 1 trial) has US protection and according too the new molecule in article (ICP-332 with global IP rights) Phase 1 trial!

All new second generation molecules now have major disparity to JAK2 it’s not if you have disparity but how much disparity you have too JAK2!

So this new selective Tyk2 (ICP-332) is a Non Receptor Tyrosine Kinsase (nRTK’s) and I think it the same in one respect but also differs from Sareums as it phosphorylates different targets, firstly the same as SDC-1801 (JH1 Domain) as it targets the Catalyic Domain but it different as this also targets the Src homology 2 (SH2) and 3 (SH3) domains, it’s got a good disparity with as mentioned in Article 400 folds of selectivity against JAK2, which being a Catalytic is very good!

https://imgur.com/a/fp1ND11

Haven’t researched just seen the tweet from Robin Davidson, you don’t really want the market crowded with Tyk2, it is validation for Tyk2 but have that already with other companys molecules, probably depends on the disease indication that is trying too be attained, it’s hard too assess because we don’t know Sareums Autoimmune indication with 1801, TL pharma is more like a duel Tyk2/JAK1 the research shows that a good differentiation and distance away from JAK2 it’s a hard one too work out though too many variables is my thoughts!

https://twitter.com/robindavison2/status/1394684206970773505?s=21

Its producing oil that matters, ie it has produce for an X amount of days at X amounts of barrels, concept turning into final product!

Big week ahead imo!